CUAMC
IBRX icon

China Universal Asset Management Company’s ImmunityBio IBRX Stock Holding History

China Universal Asset Management Company’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.46M Sell
166,687
-15,760
-9% -$119K 0.09% 167
2026
Q1 		$1.4M Buy
182,447
+21,947
+14% +$150K 0.11% 152
2025
Q4 		$318K Sell
160,500
-5,189
-3% -$11.8K 0.02% 297
2025
Q3 		$408K Sell
165,689
-11,582
-7% -$29.8K 0.03% 267
2025
Q2 		$468K Buy
177,271
+30,813
+21% +$82.9K 0.04% 245
2025
Q1 		$441K Sell
146,458
-1,296
-0.9% -$3.93K 0.04% 255
2024
Q4 		$378K Buy
147,754
+13,788
+10% +$57.4K 0.04% 276
2024
Q3 		$498K Buy
133,966
+52,716
+65% +$244K 0.05% 219
2024
Q2 		$514K Sell
81,250
-47,071
-37% -$310K 0.07% 146
2024
Q1 		$689K Buy
128,321
+51,086
+66% +$231K 0.09% 155
2023
Q4 		$388K Buy
77,235
+65,533
+560% +$206K 0.08% 159
2023
Q3 		$19.8K Buy
11,702
+5,987
+105% +$12K 0.01% 299
2023
Q2 		$15.9K Buy
5,715
+100
+2% +$283 ﹤0.01% 287
2023
Q1 		$10.2K Buy
5,615
+1,548
+38% +$4.81K ﹤0.01% 290
2022
Q4 		$20.6K Buy
4,067
+318
+8% +$1.75K 0.01% 172
2022
Q3 		$19K Buy
+3,749
New +$17.1K 0.01% 159

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SAM
SEB Asset Management Stockholm $26.6B AUM
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

China Universal Asset Management Company's IBRX Position: Q2 2026 in Review

China Universal Asset Management Company reduced its ImmunityBio (IBRX) stake by 8.6% in Q2 2026, selling an estimated $119K and leaving 166,687 shares worth $1.46M. The position accounts for 0.09% of the portfolio, ranked #167.

China Universal Asset Management Company first reported a position in IBRX in Q3 2022 and has held it in 16 quarters since. 313 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • China Universal Asset Management Company held 166,687 shares of ImmunityBio worth $1.46M as of Q2 2026.
  • China Universal Asset Management Company sold 15,760 ImmunityBio shares in Q2 2026, an estimated $119K.
  • ImmunityBio made up 0.09% of China Universal Asset Management Company's portfolio in Q2 2026, its #167 holding.
  • China Universal Asset Management Company first reported a position in ImmunityBio in Q3 2022 and has held it in 16 quarters since.
  • 313 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on China Universal Asset Management Company's 13F filing for Q2 2026, filed 24 Jul 2026.